Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171 · ASPIRE Phase 2/3Recruiting
- Lead sponsor
- Panbela Therapeutics, Inc. (Industry)
- Enrollment
- 600 (estimated)
- Start date
- 8 Aug 2022
- Primary completion
- 29 Aug 2026 (estimated)
- Study completion
- 1 Jan 2027
- Last update posted
- 6 Nov 2024
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- SBP-101 Drug
- Nab-paclitaxel Drug
- Gemcitabine Drug
- Placebo Other
Conditions and primary outcome
- Pancreatic Cancer Metastatic
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer Stage IV
Primary outcome
Overall Survival (OS) (From date of first dose up to 100 weeks or until death)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05254171.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05254171 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.